Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

Phase 4TerminatedNCT02767596

Laniado Hospital2 enrolled

Overview

The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog. Patients who fail to achieve significant improvement in diabetes control on basal insulin and Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The primary outcomes will be changes in HBA1C and weight.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus Type 2

Interventions

LixisenatideDRUG

Basal insulinsDRUG

patients are on basal insulin treatment

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Type Diabetes Mellitus on combination of basal insulin therapy and GLP1 analog, with secondary failure of non-fasting glycemic control Exclusion Criteria: * Pregnant or lactating woman * Renal failure (eGFR\<30)

Locations (1)

Bildirici Diabetes Center, Laniado Hospital

Netanya, Israel

Outcomes

Primary Outcomes

Change in hemoglobin A1c

Time frame: 16 weeks

Change in body weight

Time frame: 16 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.